The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

"I wanted to start wearing less foundation and needed a cream with SPF, so needed something quality. This stuff goes on like ...